Acrux Ltd (ASX: ACR) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Acrux Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $16.86 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 290.72 million
Earnings per share -0.002
Dividend per share N/A
Year To Date Return 27.27%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Acrux Ltd (ASX: ACR)
    Latest News

    Shot of a young scientist using a digital tablet while working in a lab.
    Healthcare Shares

    Guess which ASX healthcare stock is rocketing 110% on US product launch

    Shareholders of this stock are smiling on Wednesday. Why is it rocketing?

    Read more »

    A drawing of a rocket follows a chart up, indicating share price lift
    Share Gainers

    Why the Acrux (ASX:ACR) share price is rocketing 39% higher today

    The US FDA just gave this biotech the thumbs up...

    Read more »

    Share Market News

    ASX stock of the day: Acrux (ASX:ACR) shares soar 36% on FDA approval

    Acrux Limited (ASX: ACR) shares are soaring today after the pharma company gained a coveted FDA approval from the US…

    Read more »

    Healthcare Shares

    Why the Acrux share price skyrocketed 63% this morning

    The Acrux Limited (ASX: ACR) share price has taken off this morning, bolting out of the gates in response to a…

    Read more »

    a woman
    Share Fallers

    Insider share buying can't stop the Starpharma share price sliding again today

    The Starpharma Ltd (ASX:SPL) share price is falling again today after a shock FDA rejection.

    Read more »

    a woman
    Share Market News

    Are Mesoblast shares ready to shoot higher?

    Mesoblast limited (ASX:MSB) reported another quarter of significant cash outflows.

    Read more »

    a woman
    Share Fallers

    Why these 4 ASX shares have started the week in the red

    The A2 Milk Company Ltd (ASX:A2M) share price is one of four starting the week in the red. Here's why...

    Read more »

    a woman
    Share Fallers

    Acrux Limited (ASX:ACR) shares crash lower on patent litigation

    The Acrux Limited (ASX:ACR) share price has crashed lower today after Valeant filed a patent litigation...

    Read more »

    a woman
    52-Week Highs

    Is it too late to buy these high-flying ASX shares?

    The ResApp Health Ltd (ASX:RAP) share price is one of three at a 52-week high or better today. Is it…

    Read more »

    a woman
    Share Gainers

    These 3 small caps are storming higher today

    The Money3 Corporation Limited (ASX:MNY) share price is one of three in the small cap space storming higher today...

    Read more »

    a woman
    ⏸️ Investing

    Why these 4 ASX shares have dropped lower

    The Lynas Corporation Ltd (ASX:LYC) share price is one of four dropping lower on Thursday. Here's what you need to…

    Read more »

    a woman
    ⏸️ Investing

    Is this the "Magic Formula" to investing in ASX shares?

    Joel Greenblatt's The Little Book That Still Beats the Market would have served investors very well over the past few…

    Read more »

    ACR ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Acrux Ltd

    Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and othercountries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone TopicalSolution, and among others.

    ACR Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    11 Oct 2024 $0.06 $0.00 0.00% 123,474 $0.05 $0.06 $0.05
    10 Oct 2024 $0.06 $0.00 0.00% 28,622 $0.05 $0.06 $0.05
    09 Oct 2024 $0.05 $0.00 0.00% 34,805 $0.06 $0.06 $0.05
    08 Oct 2024 $0.05 $0.00 0.00% 35,444 $0.05 $0.05 $0.05
    07 Oct 2024 $0.05 $0.00 0.00% 11,200 $0.05 $0.05 $0.05
    03 Oct 2024 $0.05 $0.00 0.00% 9,000 $0.05 $0.05 $0.05
    02 Oct 2024 $0.05 $0.00 0.00% 343,985 $0.06 $0.06 $0.05
    01 Oct 2024 $0.05 $0.00 0.00% 964,987 $0.06 $0.06 $0.05
    30 Sep 2024 $0.06 $0.00 0.00% 737,997 $0.06 $0.06 $0.06
    27 Sep 2024 $0.06 $0.00 0.00% 15,000 $0.06 $0.06 $0.06
    26 Sep 2024 $0.06 $0.00 0.00% 226,599 $0.06 $0.06 $0.06
    25 Sep 2024 $0.06 $0.00 0.00% 383,974 $0.05 $0.06 $0.05
    24 Sep 2024 $0.06 $0.00 0.00% 39,821 $0.05 $0.06 $0.05
    23 Sep 2024 $0.05 $0.00 0.00% 33,161 $0.05 $0.05 $0.05
    20 Sep 2024 $0.05 $0.00 0.00% 74,021 $0.05 $0.05 $0.05
    19 Sep 2024 $0.05 $0.00 0.00% 42,479 $0.06 $0.06 $0.05
    17 Sep 2024 $0.05 $0.00 0.00% 121,546 $0.06 $0.06 $0.05
    16 Sep 2024 $0.05 $-0.01 -17.24% 302,428 $0.06 $0.06 $0.05
    13 Sep 2024 $0.06 $0.00 0.00% 124,920 $0.06 $0.06 $0.06

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    05 Mar 2024 Ross Dobinson Exercise 418,851 $23,036
    Conversion of securities.
    05 Mar 2024 Ross Dobinson Buy 418,851 $23,036
    Conversion of securities.
    05 Mar 2024 Donald Brumley Exercise 265,736 $14,615
    Conversion of securities. 797,210 Unlisted Rights
    20 Dec 2023 Geoffrey Brooke Exercise 138,187 $6,218
    Conversion of securities. 1,062,946 rights
    20 Dec 2023 Geoffrey Brooke Buy 138,187 $6,218
    Conversion of securities.
    20 Dec 2023 Timothy Oldham Buy 414,561 $18,655
    Conversion of securities.
    20 Dec 2023 Timothy Oldham Exercise 414,561 $18,655
    Conversion of securities. 1,062,946 unlisted rights
    05 Dec 2023 Geoffrey Brooke Issued 1,062,946 $52,084
    Issue of securities. 12,01,133 Rights
    05 Dec 2023 Timothy Oldham Issued 1,062,946 $52,084
    Issue of securities. 14,77,507 Rights
    05 Dec 2023 Ross Dobinson Issued 1,675,405 $82,094
    Issue of securities. 1,675,405 unlisted rights
    05 Dec 2023 Donald Brumley Issued 1,062,946 $52,084
    Issue of securities. 1,062,946 Unlisted Rights
    24 Nov 2023 Ross Dobinson Buy 237,610 $10,217
    Conversion of securities.
    24 Nov 2023 Ross Dobinson Exercise 237,610 $10,217
    Conversion of securities.
    24 Nov 2023 Donald Brumley Exercise 138,187 $5,942
    Conversion of securities.
    24 Nov 2023 Donald Brumley Buy 138,187 $5,942
    Conversion of securities.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Ross Dobinson Non-Executive ChairmanNon-Executive Director Jul 2012
    Mr Dobinson has a background in investment banking and stockbroking. He was a founding Director of Starpharma Holdings Limited (ASX: SPL) and was formerly a Director of Reliance Worldwide Corporation (ASX: RWC), Executive Director of Hexima Limited (ASX: HXL), Chairman of TPI Enterprises Limited (now Palla Pharma Ltd. ASX: PAL), Director of Roc Oil Company Limited (ASX: ROC) and a Director of Racing Victoria Limited.
    Dr Geoffrey E.D Brooke Non-Executive Director Jun 2016
    Dr Brooke has more than 30 years of venture capital experience. In 2014, he sold his involvement in GBS and now concentrates on privately investing in a small number of companies. He is a member of Risk and Human Capital Committee.
    Dr Timothy Oldham Non-Executive Director Oct 2013
    Dr Oldham has 20 years of life sciences business development, alliance management and sales and marketing experience in Europe, Asia and Australia. He is the Chair of the Human Capital Committee and also a member of Risk Committee.
    Mr Michael John Kotsanis Chief Executive OfficerManaging Director Nov 2014
    Mr Kotsanis has more than 30 years of experience in the global pharmaceutical industry including significant senior leadership experience. Prior to Faulding, Michael held a variety of sales and marketing positions with a German multinational pharmaceutical company over an 11-year period.
    Mr Donald Charles Brumley Non-Executive Director Jun 2021
    Mr Brumley has 30 years of experience as a senior partner of Ernst & Young, Oceania. He has experience in IPOs, transactions and audit and has advised and worked with Boards of organisations ranging from some of the largest in Australia to fast growing entrepreneurial and medium sized organisations. He is the Chair of the Risk Committee and also a member of Human Capital Committee.
    Ms Joanna Johnson Chief Financial OfficerCompany Secretary Jun 2021
    -
    Joanna Johnson Chief Financial OfficerCompany Secretary
    -
    Felicia Colagrande Product Development and Technical Affairs Director
    -
    Mark Hyman Project and Technical Development Director
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Phillip Asset Management Limited 31,847,134 10.95%
    Hishenk Pty Ltd 11,000,000 3.78%
    Mr Ross Dobinson 5,249,245 1.81%
    Dr Thomas Vui Chung Chai 4,951,985 1.70%
    Willoughby Capital Pty Ltd 4,500,000 1.55%
    Citicorp Nominees Pty Limited 4,149,492 1.43%
    Mr Christopher Murray Abbott 4,000,000 1.38%
    Ashwood River Pty Ltd 3,800,000 1.31%
    The Poole Family Superannuation Fund Pty Ltd 3,700,000 1.27%
    Mr Donald Charles Brumley 3,396,108 1.17%
    Netwealth Investments Limited 3,284,269 1.13%
    Mr Alan Jebb & Mrs Sandra Jebb 3,100,000 1.07%
    MNA Family Holdings Pty Ltd 2,800,000 0.96%
    TSO Pty Ltd 2,625,734 0.90%
    Mr Bikash Kaji Baniya 2,339,711 0.80%
    HSBC Custody Nominees (Australia) Limited 2,100,674 0.72%
    Pacific Custodians Pty Limited 2,048,427 0.70%
    Mr Ian Victor Lancini & Mrs Debra Ann Lancini 2,045,000 0.70%
    Mr Zirong Pu 2,023,000 0.70%
    Adam Jamal 1,905,719 0.66%
    Mr Michael John Kotsanis 1,511,083 0.52%
    Mr Allen James Kirby 1,500,000 0.52%
    Mr David Andrew Slobom & Mrs Linda Jane Slobom 1,409,596 0.48%
    NewEconomy Com Au Nominees Pty Limited 1,327,870 0.46%
    Mrs Nola Kendall Fletcher 1,300,000 0.45%

    Profile

    since

    Note